Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

Alessandra Cassano, Ruggero De Maria Marchiano, Armando Orlandi, Domenico Cristiano Corsi, Antonio Dello Russo, Laura Pizzuti, Antonio Giordano, Andrea Michelotti, Marco Mazzotta, Clara Natoli, Teresa Gamucci, Claudia De Angelis, Elisabetta Landucci, Lucrezia Diodati, Laura Iezzi, Lucia Mentuccia, Agnese Fabbri, Maddalena Barba, Giuseppe Sanguineti, Paolo MarchettiSilverio Tomao, Luciano Mariani, Vito Lorusso, Simona Vallarelli, Luca Moscetti, Domenico Sergi, Maria Giuseppina Sarobba, Giuseppe Tonini, Daniele Santini, Valentina Sini, Enzo Veltri, Angela Vaccaro, Laura Ferrari, Michele De Tursi, Nicola Tinari, Antonino Grassadonia, Filippo Greco, Andrea Botticelli, Nicla La Verde, Claudio Zamagni, Daniela Rubino, Enrico Cortesi, Valentina Magri, Giulia Pomati, Simone Scagnoli, Elisabetta Capomolla, Ramy Kayal, Angelo Fedele Scinto, Domenico Corsi, Marina Cazzaniga, Lucio Laudadio, Samantha Forciniti, Maria Mancini, Luisa Carbognin, Patrizia Seminara, Sandro Barni, Riccardo Samaritani, Mario Roselli, Ilaria Portarena, Antonio Russo, Corrado Ficorella, Katia Cannita, Silvia Carpano, Mirco Pistelli, Rossana Berardi, Isabella Sperduti, Gennaro Ciliberto, Patrizia Vici

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.
Original languageEnglish
Pages (from-to)7708-7717
JournalJournal of Cellular Physiology
Volume234
DOIs
Publication statusPublished - 2019

Keywords

  • Cell Biology
  • Clinical Biochemistry
  • Physiology
  • advanced breast cancer, hormonal therapy
  • endocrine resistance
  • palbociclib
  • real-world setting

Fingerprint

Dive into the research topics of 'Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience'. Together they form a unique fingerprint.

Cite this